J Korean Diabetes.  2021 Dec;22(4):221-224. 10.4093/jkd.2021.22.4.221.

Diabetes and COVID-19 Vaccination

• Choi HD
• Moon JS

• KMID: 2526204
• DOI: http://doi.org/10.4093/jkd.2021.22.4.221

Abstract

Diabetes is one of the major comorbidities associated with increased risk of mortality and severe clinical outcomes in coronavirus disease 19 (COVID-19) patients. Thus, timely and appropriate vaccination is the most effective strategy for mitigating the risk of COVID-19 infection in people with diabetes. Recent studies have shown that immune response after vaccination is significant in both diabetes and non-diabetes groups, but slightly lower in patients with diabetes. Inadequate glucose control might impair the immune response. Blood glucose monitoring is required more often than usual for several days after vaccination. If a patient’s blood glucose is not controlled adequately, appropriate management should be provided.

Keyword

COVID-19; Diabetes mellitus; Pandemics; Vaccination

Reference

1.Our World in Data. Cumulative confirmed COVID-19 cases and deaths, World. Available from:. https://our-worldindata.org/grapher/cumulative-deaths-and-cas-es-covid-19. (updated 2021 Nov 27).

2.Pal R., Bhadada SK., Misra A. COVID-19 vaccination in patients with diabetes mellitus: current concepts, uncer-tainties and challenges. Diabetes Metab Syndr. 2021. 15:505–8.

3.Korean Disease Control and Prevention Agency. Types of COVID-19 vaccines. Available from:. https://ncv.kdca.go.kr/menu.es?mid=a10119000000. (updated 2021 Nov 27).

4.Lim S., Bae JH., Kwon HS., Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021. 17:11–30.

5.Gregory JM., Slaughter JC., Duffus SH., Smith TJ., LeStourgeon LM., Jaser SS, et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic's impact in type 1 and type 2 diabetes. Diabetes Care. 2021. 44:526–32.

6.World Health Organization (WHO). Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: background document to the WHO Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing. Geneva: WHO;2021.

7.World Health Organization (WHO). Background document on the AZD1222 vaccine against COVID-19 devel-oped by Oxford University and AstraZeneca: background document to the WHO Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID19 developed by Oxford University and AstraZeneca. Geneva: WHO;2021.

8.World Health Organization (WHO). Background document on the mRNA-1273 vaccine (Moderna) against COVID-19: background document to the WHO Interim recommendations for use of the mRNA-1273 vaccine (Moderna). Geneva: WHO;2021.

9.World Health Organization (WHO). Background document on the Janssen Ad26.COV2.S (COVID-19) vaccine: background document to the WHO Interim recommendations for use of Ad26.COV2.S (COVID-19) vaccine. Geneva: WHO;2021.

10.Ali H., Al-Terki A., Sindhu S., Alahmad B., Hammad M., Al-Sabah S, et al. Robust antibody levels in both dia-betic and non-diabetic individuals after BNT162b2 mRNA COVID-19 vaccination. medRxiv 2021.DOI: doi: 10.1101/2021.07.23.21261042. [Epub ahead of print].

11.Terpos E., Trougakos IP., Karalis V., Ntanasis-Stathopoulos I., Gumeni S., Apostolakou F, et al. Kinetics of Anti-SARS-CoV-2 antibody responses 3 months post complete vaccination with BNT162b2; a prospective study in 283 health workers. Cells. 2021. 10:1942.

12.Marfella R., D'Onofrio N., Sardu C., Scisciola L., Maggi P., Coppola N, et al. Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: the CAVEAT study. Diabetes Obes Metab 2021.DOI: doi: 10.1111/dom.14547. [Epub ahead of print].

13.Lee HJ., Sajan A., Tomer Y. Hyperglycemic emergencies associated with COVID-19 vaccination: a case series and discussion. J Endocr Soc. 2021. 5:bvab141.

14.Edwards AE., Vathenen R., Henson SM., Finer S., Gunganah K. Acute hyperglycaemic crisis after vaccination against COVID-19: a case series. Diabet Med. 2021. 38:e14631.

15.Mishra A., Ghosh A., Dutta K., Tyagi K., Misra A. Exacer-bation of hyperglycemia in patients with type 2 diabetes after vaccination for COVID19: report of three cases. Diabetes Metab Syndr. 2021. 15:102151.

16.Ku CR., Jung KY., Ahn CH., Moon JS., Lee JH., Kim EH, et al. Committee of Clinical Practice Guideline of the Korean Endocrine Society. COVID-19 vaccination for endo-crine patients: a position statement from the Korean Endocrine Society. Endocrinol Metab (Seoul). 2021. 36:757–65.